The Americas interrupted the transmission of poliovirus in 1991; most Latin American and Caribbean (LAC) countries rely on the oral polio vaccine (OPV) to maintain elimination. We estimated the risk of vaccine-associated paralytic polio (VAPP) in LAC for 1992-2011. VAPP cases were identified using LAC's acute flaccid paralysis (AFP) surveillance system. VAPP was defined as any AFP case with residual paralysis 60 days following onset that did not have a clear alternative etiology and with isolation of vaccine-strain poliovirus. Recipient VAPP cases were defined as those with paralysis onset 4-40 days following OPV; cases meeting these criteria but with unknown residual paralysis were added. Nonrecipient VAPP cases were defined as those in individuals with an unknown vaccination status, those in individuals who received 0 doses, or those with paralysis onset outside the 4-40-day interval. Of 40 926 AFP cases reported in LAC from 1992-2011, we identified 72 recipient and 119 nonrecipient VAPP cases. The estimated risk of recipient VAPP was 1 case per 3.15 million newborns (95% confidence interval [CI], 1 case per 2.56-4.10 million newborns), and the estimated overall risk was 1 case per 1.19 million newborns (95% CI, 1 case per 1.04-1.39 million newborns). In this multicountry VAPP analysis in a postelimination period, we found that the risk of VAPP in LAC was lower than previously estimated.
In 1988, the World Health Assembly (WHA) established the goal of eradicating polio by 2000 [1] . Although polio has yet to be eradicated, significant progress has been made. A total of 350 000 wild poliovirus cases were reported in 1988, compared with 223 in 2012 [2] . Today, polio is only endemic to Afghanistan, Nigeria, and Pakistan, with periodic importations and reestablished transmission of the virus in several countries in recent years [2] . Moreover, the international community has redoubled efforts to rid the world of the disease: the WHA declared global polio eradication a public health emergency in May 2012 [3] .
A key component for the success of polio eradication has been the oral polio vaccine (OPV). Every country in the world, excluding Iceland and Sweden, relied on OPV to eliminate polio [2] . The Americas Region, which includes Latin America and the Caribbean (LAC) and North America (Canada and the United States), interrupted the indigenous transmission of wild poliovirus in 1991 by using OPV and was certified as free of polio in 1994 [4] . Using similar strategies, the Western Pacific and European regions were certified free of polio in 2000 and 2002, respectively. In 2012, all LAC countries used OPV in routine and/or biannual national immunization days (NIDs), with the exception of the French Departments, the United Kingdom overseas territories of Bermuda and the Cayman Islands, and the Dutch autonomous islands of Aruba and Saint Martin.
Cases of vaccine-associated paralytic poliomyelitis (VAPP) and paralytic polio caused by vaccine-derived polioviruses (VDPVs) are the known risks associated with OPV. VAPP is known to occur in both the recipient of the vaccine and in close contacts of recently vaccinated individuals, and the polio strain isolated is the vaccine strain. In contrast, VDPVs originate from vaccine-strain viruses that then mutate to regain virulence and have the ability to circulate within communities, similar to wild poliovirus [5] . Once the virus is eliminated from the human population worldwide, the only sources of paralytic polio will be polioviruses stored in laboratories and OPV, if used by countries. As the final push toward global eradication is made, the risk of VAPP is increasingly important to policy makers deciding when and how to transition from OPV to inactivated polio vaccine (IPV) [6] . With the intention of minimizing VAPP and polio due to type 2 VDPV, the Strategic Advisory Group of Experts on Immunization recently called for all countries currently using OPV to transition from trivalent to bivalent OPV and to introduce at least 1 dose of IPV into their routine immunization schedules as a step toward eventual cessation of all OPV use [3, 7] . Despite VAPP's relevance to the polio endgame, data on VAPP are limited. Most existing studies are outdated (generally >10 years old), focus on a single country, and examine a period in which wild poliovirus was still endemic to the area [4, [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] . The most recent study in LAC estimated the VAPP risk to be 1 case per 1.5-2.2 million doses administered during 1989-1991, a time in which wild poliovirus was still circulating in the Americas [4] . In this study, we estimate the risk of VAPP among recipients and nonrecipients of OPV in LAC in the postelimination period of 1992-2011.
METHODS

Data Sources
As part of regional polio elimination strategies, LAC countries investigate all cases of acute flaccid paralysis (AFP) in children aged <15 years. AFP is formally defined in LAC as any flaccid paralysis with acute onset for any reason other than severe trauma [26, 27] . The LAC countries also use standardized definitions for polio and clinical and laboratory criteria for the disease's differential diagnosis. A stool specimen is required to test for poliovirus [28] . Cases not classified as polio receive a final diagnosis, typically made by epidemiologists or national classification committees [26, 27] .
Per international standards, an AFP surveillance system in an area without endemic poliovirus transmission is considered sensitive when an annual rate of at least 1 non-polio-associated case of AFP per 100 000 children aged <15 years is reached [15] . During 1992-2011, the average AFP rate in LAC was 1.35 cases per 100 000 children aged <15 years (range, 1.12-1.65 cases) [29] . Each week, approximately 33 000 notification units in LAC submit reports of AFP cases to local and national levels and to the Pan American Health Organization (PAHO). Cases are entered into the Polio Eradication Surveillance System (PESS) and the Integrated Surveillance Information System (ISIS), 2 case-based databases and electronic platforms maintained by PAHO [28] . We used PESS and ISIS data to identify potential cases of VAPP. Data on VAPP cases extracted from the PESS have been published previously [5] . Our analysis includes data from all 33 countries and 6 United Kingdom overseas territories in LAC during 1992-2011, excluding unreported data from Costa Rica in 2005.
Virus Isolation
Stool specimens were processed in the regional polio laboratory network, which is part of the Global Polio Laboratory Network (GPLN). All laboratories undergo annual accreditation to ensure compliance with regulatory guidelines and are subject to quality control evaluations [26, 27] . Virus strains are isolated from stool specimens, cultured in rhabdomyosarcoma and Hep-2C cells, and characterized by serotype by use of genotypic probes and polymerase chain reaction analyses [4] . In 1999, following GPLN recommendations, laboratories began using L20B cells instead of Hep-2C cells owing to the increased specificity of the former cells [4, 30] . Other aspects of the isolation and genotyping processes remained the same and comply with updated standards of the GPLN.
Risk Analysis
No cases of wild poliovirus were reported in LAC during the period studied. Cases previously identified as VDPV were excluded from the analysis because of the affected individuals' ability to transmit and because the mutated virus behaves in a fashion similar to that of wild poliovirus. We defined VAPP as any AFP case with residual paralysis 60 days following onset that was not due to trauma, tumor, or other obvious etiologies and with isolation of vaccine-strain poliovirus from a stool specimen taken at any time following paralysis. Cases with an onset of paralysis occurring 4-40 days following OPV administration were defined as recipient VAPP (group A). To use a more sensitive definition, potential recipient cases with viral isolation but with an unknown status of residual paralysis were also classified as recipient VAPP (group B). Cases with an unknown status or date of OPV receipt or with an onset of paralysis outside the 4-40-day interval were defined as nonrecipient VAPP (group C). The term "nonrecipient VAPP" includes contact cases mentioned in other studies and potential recipient cases with unknown dates of OPV administration [15] . Potential nonrecipient cases with viral isolation and with an unknown status of residual paralysis were added if they were diagnosed as VAPP in the field (group D).
Not isolating a poliovirus does not necessarily indicate that the virus was never present, particularly for specimens taken >14 days following paralysis onset. To account for such cases, we conducted a sensitivity analysis, assuming that the proportion of AFP cases with positive, timely specimens represented the proportion of cases for which a vaccine strain could have been isolated had a timely sample been taken. We then applied the ratio to the subgroup for which specimens were obtained >14 days after paralysis onset. Following a similar procedure, we calculated the number of cases lacking specimens that would have theoretically tested positive for VAPP had a specimen been taken.
Risks of VAPP per child were calculated by dividing the number of cases by annual birth averages from LAC [31] . Similarly, per-dose risks were calculated using a conservative estimate of OPV doses administered in LAC during 1992-2011, using the World Health Organization/United Nations Children's Fund coverage estimates for 3 doses of OPV (OPV3), as well as doses administered in Brazil and Mexico during NIDs in 1992-2011 and doses administered during Vaccination Week in the Americas in 2006-2011 [32, 33] . Because of the lack of coverage estimates, Caribbean overseas territories were excluded from the dose estimate. Mexico OPV3 coverage data from 2007 through 2011 were also excluded because the country discontinued OPV use in its routine program in 2007. The estimate of OPV doses does not account for dropout rates (ie, administration of more OPV1 doses than OPV2 and OPV3 doses) or NIDs conducted in LAC countries besides Brazil and Mexico.
To calculate the first-dose risk of recipient VAPP, we divided the number of VAPP cases following the first dose of OPV by the LAC birth cohort during 1992-2011. Because LAC countries give booster OPV doses and most countries administer OPV in campaigns, we assumed that all children born in LAC had received at least 1 OPV dose. Risks are presented as cases per million children in the average annual birth cohort and per million OPV doses, with 95% confidence intervals (CIs).
For cases of recipient and nonrecipient VAPP, we analyzed age, sex, fever at onset of paralysis, type of poliovirus, and vaccine dose. To have a sense of potential misclassifications, we compared characteristics of cases identified as recipient VAPP to those of nonrecipient cases, and we compared characteristics of cases diagnosed as VAPP in the field to those with other or unknown diagnoses. Because there is not a distinction in the PESS/ISIS between vaccine doses administered during NIDs and those administered as part of the routine immunization program, comparisons of VAPP risks at this level of administration could not be made. The last step of our analysis considered the distribution of VAPP cases by country and year; we used the Runs test to assess temporal trends. We calculated risks of recipient VAPP in countries according to the steps previously described. χ 2 and Yates tests were used for these comparisons; P values of < .05 were considered statistically significant. All data were cleaned and extracted using Microsoft Standard Query Language. We completed statistical analyses (Yates corrected, when appropriate), using programs on statspages.com.
RESULTS
During 1992-2011, LAC countries and territories reported 40 926 AFP cases. Of these, 526 (1%) had no clinical information, and 19 902 (49%) were recorded as not having residual paralysis; these cases were excluded from further analysis. Additionally, 6751 cases (16%) were recorded as having residual paralysis 60 days following onset of paralysis and 13 747 (33%) had an unknown status of residual paralysis. Among all cases, 23 634 (58%) had a recorded date of last OPV receipt, 37 337 (91%) had 1 or more specimens, and 31 570 (77%) had specimens taken within 14 days of paralysis onset. Twenty-six cases classified as VDPVs (3 from Argentina, 1 from Colombia, 13 from the Dominican Republic, 8 from Haiti, and 1 from Peru) were excluded from the analysis. A total of 72 cases were diagnosed as VAPP in the field during 1992-2011.
Of 6751 cases with residual paralysis, 209 had a specimen from which a vaccine-strain poliovirus was isolated; of these, 62 were excluded because of diagnoses incompatible with VAPP, including trauma (4 cases), tumor (2), intoxication (3), encephalitis (10), conditions of the central nervous system (10) , and other etiologies (33) . Of the remaining 147 cases, 41 occurred within the 4-40-day interval from vaccination to paralysis onset. These cases were classified as recipient VAPP in group A ( Table 1 ). The remaining 106 cases were classified as nonrecipient VAPP and placed in group C.
Of 14 273 cases with an unknown status of residual paralysis, 251 had a vaccine poliovirus isolated; 117 of these were excluded owing to clear alternative etiologies, such as trauma (1 case), tumor (3), encephalitis (9), intoxication (69), conditions of the central nervous system (9) , and other diagnoses incompatible with polio (26) . Of the remaining 134 cases, 31 occurred within the 4-40-day interval (group B) and were added to group A, yielding 72 recipient VAPP cases, for a risk of 1 case per 3.15 million newborns (95% CI, 1 case per 2.56-4.10 million newborns) in the average annual birth cohort. Thirteen cases diagnosed as VAPP (group D) were added to group C, yielding 119 nonrecipient VAPP cases and an estimated risk of nonrecipient VAPP of 1 case per 1.91 million newborns (95% CI, 1 case per 1.62-2.33 million newborns). The remaining 90 cases with an unknown status of residual paralysis and with neither a vaccine-poliovirus isolate nor a diagnosis compatible with polio were excluded.
The overall risk of VAPP (n = 191 cases) was estimated to be 1 case per 1.19 million newborns (95% CI, 1 case per 1.04-1.39 million newborns) and 1 case per 7.68 million doses administered (95% CI, 1 case per 6.73-8.95 million doses administered). Using data from our sensitivity analyses to add 11 cases, the overall VAPP risk increased to 1 case per 1.12 million newborns (95% CI, 1 case per .99-1.30 million newborns) and 1 case per 7.26 million doses administered (95% CI, 1 per 6.38-8.42 million doses administered).
Recipient cases were more likely than nonrecipient cases to be aged <5 years (96% vs 71%; P < .001), to present with fever at onset (69% vs 54%; P = .059), to have poliovirus type 3 (55% vs 38%; P ≤ .001), to occur in males (74% vs 57%; P = .033), and to have been diagnosed as VAPP in the field (53% vs 21%; P ≤ .001; Table 2 ). The average number of days between OPV receipt and paralysis onset was 17 (median, 16 days; range, 4-37 days). Most recipient VAPP cases occurred following the first OPV dose (49% [33/67] ; data for 5 were unknown). The first-dose risk of VAPP was calculated to be 1 case per 6.88 million newborns (95% CI, 1 case per 5.13-10.45 million newborns), whereas the subsequent-dose risk of recipient VAPP was 1 case per 31.79 million doses (95% CI, 1 case per 24.19-46.33 million doses). If AFP cases diagnosed as Guillain-Barré syndrome (n = 16) in the field were to be removed from this analysis, 59% of the remaining cases (30/51; data for 5 were unknown) occurred following the first dose.
Of the 119 nonrecipient VAPP cases (groups C and D), 17 (14%) occurred <4 days from the last OPV vaccination, 7 (6%) occurred within 41-75 days, 44 (37%) occurred >75 days, and 51 (43%) lacked information on OPV receipt. Nonrecipient cases diagnosed as VAPP in the field occurred in younger individuals, compared with nonrecipient VAPP cases with other diagnoses (P = .004), and were more likely to present with fever (P = .04). However, in restricting these comparisons to nonrecipient cases diagnosed as VAPP in the field versus recipient VAPP, we found no statistical differences.
The distribution of 72 recipient VAPP cases occurred in 15 countries, whereas the distribution of 119 nonrecipient cases occurred in 15 countries. Recipient VAPP rates in countries with VAPP cases ranged from 1 case per 1.00 million children to 1 case per 11.60 million children (Table 3) . Recipient risks in the most populous LAC countries were 1 per 2.36 million children and 1 per 4.17 million children, respectively. While no clear relation was found between the incidence of VAPP and such factors as AFP surveillance indicators, OPV3 coverage, or the percentage of cases with a timely specimen (<14 days), some countries with high VAPP risks had low infant mortality rates (Table 3 ). An average of 3.6 recipient VAPP cases were identified each year (median, 3 recipient VAPP cases), with more cases identified earlier in the study period, directly following polio elimination. 
DISCUSSION
The present study is the largest of its kind, spanning 20 years and a large geographical area in the region that first eliminated polio. We identified 72 cases of recipient VAPP and 119 cases of nonrecipient VAPP, resulting in an overall estimated risk in LAC of 1 case per 1.04-1.39 million newborns and 1 case per 6.73-8.95 million doses administered. This rate is lower than the risk of 1 case per 0.29 million children reported in LAC during 1989-1991 (139 cases among 39 663 000 live births) [4] . However, comparisons between the studies must be made with caution. Although both studies used AFP surveillance data to identify VAPP cases, the previous study analyzed AFP cases reported when there was still endemic transmission of wild poliovirus in LAC and used a VAPP case definition that did not require isolation of a VDPV from stool specimens. Because only 26 of 85 recipient VAPP cases (31%) in the previous study had VDPV isolates, some cases with clinical symptoms compatible with both VAPP and wild poliovirus may have been misclassified as VAPP. Changes in surveillance practices and isolation techniques in LAC may also help to explain the studies' varying results. Improvements in the cold chain and the use of more-sensitive cell lines to culture polioviruses in the region's laboratories may have increased the probability of detecting polioviruses. Conversely, the 1997 recommendation by PAHO's Technical Advisory Group on Vaccine-Preventable Diseases suggesting that countries collect 1 stool specimen rather than 2 may have decreased the probability of detecting the virus [30] . This recommendation may in part also explain why more VAPP cases were detected around the time of elimination. Additionally, the greater number of cases detected during this period, although not statistically significant, may be explained by the increased number of OPV doses administered during the massive vaccination campaigns conducted in the early years following elimination.
International comparisons of VAPP risk are complicated by differences in surveillance systems among countries and by differences in case definitions and methods among studies. In the United States, for example, the most recent study analyzed VAPP cases in people of all ages, compared with only those aged <15 years in this analysis [19] . However, the international literature does achieve some consensus on the characteristics of VAPP cases. VAPP cases have been reported more frequently in males, children aged <5 years, and following the first dose of polio vaccine. VAPP cases have also disproportionately presented with fever and been linked to Sabin virus 3 rather than to viruses 1 and 2 [4, [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] . (17) 10 (8) 22 (12) a Not all percentages sum to 100%, owing to rounding. b Data are from [34] .
c Data are from [29] .
d Data are from [35] .
e Country D represents a group of countries/territories that report AFP data jointly. In deciding how best to evaluate VAPP, we assessed the risk to an individual child irrespective of the number of doses administered [16] . We used national birth cohort data to calculate risk but provide first-dose and per-dose rates for comparison. Our overall dose risk of VAPP in LAC, estimated at 1 case per 7.68 million doses, is higher than the risk most recently reported in Brazil (10.7 million doses) [13] and lower than those reported in Japan (2.0 million doses) [10] , India (4.1-4.6 million doses) [15] , Canada (2.4 million doses) [24] , the United States (2.5 million doses) [19] , and other countries ( Table 4) . The reasons for this discrepancy may be related to case definitions, surveillance systems, susceptibility, environment, differences in vaccine types used by countries, or other unknown factors.
During 1970-1979, the World Health Organization first assessed the risk of VAPP in 13 countries and did not find a clear explanation for the higher rate observed in some areas [17] . In our study, we found significant variations of VAPP among countries, ranging from no cases to 1 case per 1.00 million newborns in country S to 1 case per 11.60 million newborn in country V. Many of the aforementioned reasons concerning observed differences in VAPP rates among studies may also explain discrepancies among countries. Although we did not find any association between VAPP risk and AFP surveillance indicators, we observed lower rates in some countries with higher infant mortality rates. Since immunologically abnormal children have been reported to possess a 3200 times greater risk of developing VAPP, this difference may reflect the quality of health systems in wealthier countries and the increased survival of children with such disorders [37] .
Possible limitations of this study are likely related to the sensitivity of AFP surveillance to detect VAPP cases, potential misclassification of cases, and inaccurate denominators. Although underreporting of cases is a possibility, the region's AFP rates surpass international standards and have remained similar to those before elimination [38, 39] . Regarding data quality, 3589 of 40 916 AFP cases (9%) were not tested for polio. Sensitivity analyses were performed to correct for data limitations, but missed cases remain a possibility. Misclassification of cases is likely due to missing data (ie, misclassification of recipient cases as nonrecipient cases, owing to missing data on OPV receipt). However, missing data and underreporting of cases, even in the extreme, do not explain the low VAPP risk that we observed. If we doubled the number of VAPP cases, the VAPP risk in LAC would be 1 case per 0.59 million newborns or 1 case per 3.84 million doses-risks still lower than those previously estimated in LAC and other settings. Moreover, our analysis provided a conservative estimate of VAPP. Guillain-Barré syndrome is part of the differential diagnosis of polio that is most distinguishable from paralysis caused by poliovirus (eg, age of onset and progression of paralysis). However, to capture the greatest potential number of VAPP cases, we included cases diagnosed as GBS in the field as recipient VAPP, even if a disproportionate number of these (13/16) did not occur following the first OPV dose, as is most commonly reported for VAPP [27] . Likewise, unlike some studies, we included many cases with an unknown status of residual paralysis, knowing that most cases left without data on residual paralysis occur in children who recover following acute paralysis. We also used a broad definition of nonrecipient VAPP that likely resulted in the inclusion of many non-VAPP cases. This is illustrated by the significant differences between recipient and nonrecipient cases and by differences in characteristics between the cases we identified as VAPP and those reported in the literature. For example, VAPP in children aged ≥5 years is relatively rare. In a recent re-analysis of VAPP cases from Hungary, no cases (0/46) occurred in children aged ≥5 years; nevertheless, 20% of cases (38/191) classified as VAPP in our study occurred in this age group [22] . Finally, our denominator estimates are a likely underestimation of the real number of OPV doses administered in LAC during 1992-2011.
Ultimately, global polio eradication will result in the elimination of paralytic polio cases caused both by wild polioviruses and the Sabin vaccine. As the world enters the last stages of eradication, when the risk of paralysis caused by wild poliovirus is diminishing, decision makers and communities will become increasingly concerned with the risk of VAPP. Accordingly, the introduction of IPV, whether as the only polio vaccine or in sequential schedules, will be a matter of affordability and competing public health priorities, weighed against the most reliable risk estimate of VAPP [40, 41] . We found the incidence of VAPP in LAC to be lower than previously estimated. Our findings highlight the importance of assessing the risk of adverse events, particularly one as important as VAPP, in low-and middle-income countries where wild poliovirus has already been eliminated.
Notes
